Description
Erenumab is designed to specifically block the CGRP receptor, which plays a critical role in migraine activation. It is being co-developed by Novartis and Amgen.
Usage Rights & Restrictions
This media asset is free for editorial broadcast, print, online and radio use. It is restricted for other purposes.